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Abstract
In the present study, azothioprine, chloroquine, D-penicillamine,
methotrexate and sodium aurothiomalate (gold salt) were
evaluated for possible disease-modifying effects in the adjuvant-
induced arthritis model of human rheumatoid arthritis in rats.
Gait analysis was used to examine the role of disease-modifying
antirheumatic drugs in the development of pain. Body weights
were also measured to monitor the progression of disease and
the systemic antiarthritic effects of the test compounds used in
this study, as well as their systemic toxicity. Our results showed
that azothioprine (5 mg/kg/day), chloroquine (12.5 mg/kg/day),
sodium aurothiomalate (2.5 mg/kg/day) and methotrexate (1
mg/kg/week) not only inhibited the macroscopic changes such
as erythema and swelling of limbs, but also exhibited significant
reversal of gait deficits seen in the untreated or saline-treated
arthritic rats. No reduction in the body weights were observed in
the arthritic rats treated with azothioprine, chloroquine, sodium
aurothiomalate and methotrexate. D-Penicillamine (12.5 mg/kg/
day), however, showed a significant reduction (P < 0.03) in the
body weights of the arthritic rats over a period of 22 days;
furthermore, it was unable to show any reduction in arthritic
score (P  < 0.1). In earlier experiments, chloroquine and
methotrexate failed to suppress carageenan-induced edema,
suggesting that the mode of antiarthritic action may be different
from those of nonsteroidal anti-inflammatory agents. Since these
disease-modifying antirheumatic drugs are reported to have an
immunomodulatory role, especially the gold salt, which
influences the monocyte–macrophage system, it is suggested
that the observed antiarthritic effects of disease-modifying
antirheumatic drugs may be partly attributed to their
immunomodulatory activity.
Introduction
Chronic pain, a devastating and widespread problem, is a syn-
drome that cuts across traditionally defined disciplinary
boundaries within the health sciences. Patients with chronic
pain, compared with all other medical conditions, suffer dra-
matic reductions in physical, psychological and social wellbe-
ing [1-3]. Within this group of patients, arthritis is the second
largest self-reported cause of pain [4]. Although there is no
rheumatoid arthritis cure, there are effective treatments that
can alleviate the symptoms and improve the quality of life. The
nonsteroidal anti-inflammatory drugs and glucocorticoids are
largely used for treatment of rheumatoid arthritis in spite of
their systemic, gastric and renal toxicities [5-11]. These cur-
rently available analgesic and anti-inflammatory drugs are
clearly not adequate therapy. In addition to these classical
available therapies, there are several reports regarding the use
of disease-modifying antirheumatic drugs (DMARDs), which
act as potentially effective therapies for rheumatoid arthritis
[12,13]. DMARD treatment is currently based on symptomatic
relief of pain and inflammation associated with arthritis to
increase joint function and mobility.
In order to study the effects of DMARDs in the progression of
disease, we have used the adjuvant-induced arthritis model in
the rat. This model has biochemical and pathological features
similar to rheumatic disease in human, and merits investigation
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[14-19]. In this model, disease is characterized by joint pain,
joint stiffness, joint swelling and tenderness, and muscle wast-
ing leading to weight loss [20-22]. The aim of the present
study was to identify the antiarthritic and antinociceptive
effects of the DMARDs azothioprine (AZ), chloroquine (CQ),
D-penicillamine (D-PEN), sodium aurothiomalate (gold salt
(GS)) and methotrexate (MTX), and to measure any effect of
these drugs on gait. Gait analysis allows highly sensitive, non-
invasive detection and evaluation of many pathophysiological
features, such as those occurring in Alzheimer's disease,
arthritis, pain, Parkinson's disease, neuromuscular and skeletal
muscle diseases. In addition, the method of gait analysis
showed good evidence of reproducibility and reliability in our
earlier studies [23,24]. It is suggested that changes in gait
may be considered a potential marker of chronic pain.
Materials and methods
Animals
Female Sprague–Dawley rats weighing 215–230 g (8–10
weeks) were used in the study. The animals were kept at 21 ±
2°C on a 12-hour light/dark cycle with free access to standard
laboratory rat food pellets and water. The ethical guidelines of
the International Association for the Study of Pain in conscious
animals were followed [25]. Rats were randomly distributed to
each treatment group of six animals. The group size was deter-
mined as the minimum number of rats for valid statistical anal-
yses based on a pilot study by our group. The group size of six
has an 80% power to detect differences in the means.
Induction of arthritis
Lyophilized Mycobacterium tuberculosis H37Ra (MT H37Ra;
DIFCO Laboratories, Detroit, MI, USA) was used as an adju-
vant to induce arthritis. Fresh adjuvant was prepared on the
same day as arthritis was induced. A volume of 0.1 ml of a 1
mg suspension of MT H37Ra was injected intradermally at the
base of the tail using a sterile hypodermic needle under
anesthesia with a combination of ketamine/xylazine in the dose
of 20 mg/kg/5 mg/kg (intraperitoneal). Treatment was initiated
on the same day of arthritis induction.
Drugs
The reference drug indomethacine and the DMARDs (AZ, CQ,
D-PEN, GS and MTX) were purchased from Sigma Chemical
Company (St Louis, MO, USA). The vehicle (saline) and drugs
were administered intraperitoneally – except for GS, which
was administered subcutaneously. The doses of drugs used in
the present study were selected by perusal of the literature
and preliminary dose-finding studies to obtain regimens that
had no effect on gait in nonarthritic rats. In addition, concurrent
test control rats were administered only with saline.
Clinical assessment of collagen-induced arthritis
Rats were evaluated on alternate days for arthritis using a mac-
roscopic scoring system, where 0 = no signs of arthritis, 1 =
swelling and/or redness of the paw or one digit, 2 = two joints
involved, 3 = more than two joints involved, and 4 = severe
arthritis of the entire paw and all digits [26,27]. The arthritis
severity score for each rat was calculated by adding the
scores for each individual paw.
Measurement of hind paw hyperalgesia and edema
The method for measuring hyperalgesia has been described
previously [28]. The tendency of normal (naive), control and
arthritic rats to vocalize following flexion of the tarsotibial joints
of both hind paws was tested daily for 22 days starting from
day 0. Hyperalgesia is reported as the mean ± standard error
of the mean number of vocalizations following five flexions of
the hind limb tarsotibial joints, considering maximal hyperalge-
sia (value = 1) when five vocalizations were obtained following
five flexions of the paws.
The clinical severity of arthritis was also determined by quanti-
tating the change in the paw volume (as an indicator of edema)
with a plethysmometer (model 7140; Ugo Basile, Varese, Italy)
following the hyperalgesia test. The advantage of using this
method over diameter measurements of tibiotarsal joint is that
it measures the limb in three dimensions and therefore takes
into account any variability of the pattern of swelling of individ-
ual limbs. The volume of a hind paw is reported as the mean ±
standard error of the mean in milliliters. All measurements were
made at the same time of day. The body weight and hind paw
volumes were measured in both the control and test groups on
days 0 and then on alternate days until day 22 when the exper-
iment ended.
Gait analysis
Locomotion was recorded in test and control groups at the
beginning of an experiment and was used as the baseline
reading (day 0). The apparatus used for this purpose was the
TreadScan system (Clever Sys. Inc., Reston, VA, USA). This
system records a video of an animal (mouse or rat) running on
a transparent treadmill as the input. A mirror is placed at an
angle of 45° below the belt section of the chamber, which
allows the viewing of floor/paw contacts. The video essentially
captures the footprints of the animal during exercises on the
treadmill. The software provided with this system (TreadScan)
can analyze the video, and can determine various characteris-
tic parameters that are related to the pathophysiological con-
ditions. The parameters measured in this study include the
stance time (paw in contact with the floor), the swing time
(paw in the air), the stride length and the running speed.
Statistical analysis
Statistical Package for the Social Sciences software (SPSS
Inc. Chicago, IL, USA) was used to analyze the data. Through-
out the study, the mean ± standard error of means was used
to describe the data in the figures. The data were analyzed
using two-way analysis of variance. Bonferroni's post-hoc test
was used to determine which group means differ. With this
test the SPSS Inc. software automatically adjusts theAvailable online http://arthritis-research.com/content/9/5/R91
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significant level for the multiple comparisons to avoid spurious
significant differences being identified (any values <0.05 were
considered significant). The Mann–Whitney U test was used
for nonparametric data (inflammation scores).
Results
Effects of DMARDs on clinical signs of adjuvant-induced 
arthritis
After day 10, animals began to show evidence of clinical
inflammation in one or both hind paws. The first manifestation
of disease was erythema of one or more ankle joints, followed
by involvement of the metatarsal and interphalangeal joints.
The typical time course for the development and progression
of disease, as assessed by the mean arthritis severity score
and the paw volume, is shown in Figures 1 and 2. Signs of an
arthritic score of 3 in untreated arthritic rats, in arthritic rats
treated with saline only or in arthritic rats treated with D-PEN
were evident at day 10. The arthritic rats treated with AZ, CQ,
GS, MTX and indomethacine, however, showed a score of 2
on day 10. The disease was progressive, with joint recruitment
following the same pattern: tarsal, metatarsophalangeal and
then interphalangeal. In the vehicle and nontreated arthritic
group, the incidence of disease was 100% (that is, all animals
in the group were affected) at day 12, and remained as such
throughout the duration of the experiment. In contrast, treat-
ment with indomethacine, AZ, CQ, GS and MTX exerted a sig-
nificant attenuation in the incidence of adjuvant-induced
arthritis: 80% with GS treatment (P < 0.02), 70% with AZ
treatment (P < 0.05), 60% with CQ and indomethacine treat-
ment (P < 0.05) and 50% with MTX treatment (P < 0.05).
Hyperalgesia, the increase in vocalization in response to
forced flexion of the tarsotibial joints, was evident from day 11
in arthritic animals, reaching a maximum value by the end of the
experiment. Once the treatment was started, the animals in the
arthritic groups treated with AZ, with CQ, with GS, with MTX
and with indomethacine showed a marked decrease in the
vocalization compared with their concurrent arthritic control
animals.
A large increase was observed in the hind paw volume of
untreated, saline-treated and D-PEN-treated arthritic rats com-
pared with nonarthritic rats. Analysis of variance performed on
the overall data showed that this increase in the paw volumes
became significantly different from that of nonarthritic rats from
day 10 onwards (P < 0.006). It was observed that the arthritic
rats treated with AZ, with CQ and with GS showed a slight
nonsignificant increase in their paw volume compared with
normal control rats from day 8 to day 12. In contrast, arthritic
rats treated with MTX and indomethacine showed a gradual
but also nonsignificant increase in their paw volumes until the
end of the experiment.
Figure 1
Arthritis severity scores in rats during the development of adjuvant- induced arthritis Arthritis severity scores in rats during the development of adjuvant-
induced arthritis. Effect of azothioprine (AZ), chloroquine (CQ), D-peni-
cillamine (D-PEN), sodium aurothiomalate (gold salt (GS)) and meth-
otrexate (MTX) on the time course of the development and progression 
of arthritis, shown as the arthritis severity scores measured over a 
period of 22 days. Results are the mean ± standard error for six animals 
in each group. AIA, adjuvant-induced arthritis; DC, drug control; NT, no 
treatment.
Figure 2
Time course of the change in hind paw volume after the induction of  arthritis Time course of the change in hind paw volume after the induction of 
arthritis. Rats in all arthritic groups showed an increase in their paw vol-
ume until day 8; however, this increase in the azothioprine (AZ)-treated, 
chloroquine (CQ)-treated and sodium aurothiomalate (gold salt (GS))-
treated arthritic rats was not significantly different from the normal con-
trol rats, and also no further increase in the paw volume was noticed in 
these groups. In contrast, arthritic rats treated with methotrexate (MTX) 
and indomethacine showed a gradual increase in their paw volume over 
a period of 22 days, but this increase was nonsignificant compared 
with normal control rats. The arthritic rats treated with D-penicillamine 
(D-PEN) or saline showed a significant increase in their paw volume 
over the period of 22 days (P < 0.006). Inbox pictures, difference 
between the arthritic rat paw and the normal rat paw. Results 
expressed as mean ± standard error (n = 6). AC, arthritic control; AIA, 
adjuvant-induced arthritis; DC, drug control; NT, no treatment; Sal + 
Art, saline and arthritis.Arthritis Research & Therapy    Vol 9 No 5    Simjee et al.
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The body weights of the tested animals were not significantly
different between the groups before commencement of the
study. In the first 6 days the increment in body weight was sim-
ilar in all groups and no significant differences were seen
between them. After day 8, however, a gradual loss in body
weight was observed that become significant on day 10 for
untreated, saline-treated and D-PEN-treated arthritic rats as
compared with the normal control rats. This weight loss was
consistent until the end of the study (Figure 3). In contrast, the
nonarthritic rats or the arthritic rats treated with AZ, with CQ,
with GS, with MTX and with indomethacine showed no reduc-
tion in their body weights. The Bonferroni's post-hoc test for
the individual time period showed that the significant differ-
ence in the mean body weight change of untreated arthritic
rats and saline-treated nonarthritic rats started from day 10 to
day 22 (P < 0.04). No significant difference, however, was
observed within arthritic groups treated either with AZ, with
CQ, with GS, with MTX and with indomethacine.
Gait parameters
The speed or velocity of the nonarthritic rat showed little vari-
ation over the 22-day experiment, and was unaffected by drug
treatment (Figure 4). Arthritic rats untreated or treated with
saline or D-PEN showed a gradual decrease in their velocity
from day 2 onwards. This was statistically significant on day 6
(P < 0.004). The AZ, CQ, MTX and indomethacine treatments
of the arthritic rats showed a decrease in their speed from day
2 to day 12, but this decrease in the speed was not signifi-
cantly different from the normal control rats. The arthritic rats
treated with GS showed a slight nonsignificant decrease in
their velocity from day 8.
The treatments with AZ, with CQ, with GS, with MTX and with
indomethacine given to the arthritic rats showed a smaller
decrease in the stride length from day 2 to day 6 (Table 1);
thereafter, animals exhibited a reversal in the stride length
compared with the untreated arthritic rats or the D-PEN-
treated arthritic rats, so much so that the stride lengths were
indistinguishable from normal rats from day 16 onwards.
Arthritic rats untreated or treated with saline or D-PEN showed
a steady reduction in their stride length over a period of 22
days. This reduction in the stride length became significant
from day 10 onwards when compared with normal control rats
(P < 0.01). Table 1 compares the day 0 values with the day 22
values to illustrate these effects. Arthritis also caused an
increase in the stance time and the swing time from day 4
onwards. Administration of GS and of indomethacine, how-
ever, significantly decreased the gait deficits seen in untreated
or saline-treated arthritic rats from day 6 onwards (P < 0.003).
The arthritic rats treated with AZ, with CQ and with MTX were
able to show a significant reversal in these gait parameters
only after day 16 (P < 0.05 for stance time and P < 0.02 for
swing time) when compared with untreated arthritic rats.
Discussion
The treatment of rheumatoid arthritis has gone through many
major changes in the past. The concept that drugs should be
used to slow down damage caused by the disease rather than
Figure 3
Time course of body weight changes in rats with adjuvant-induced arthritis Time course of body weight changes in rats with adjuvant-induced arthritis. Effect of disease-modifying antirheumatic drugs (DMARDs) on the body 
weight change of the arthritic rats, measured over a period of 22 days. (a) Effect of D-penicillamine (D-PEN) and sodium aurothiomalate (gold salt 
(GS)) on body weights of adjuvant-induced arthritis (AIA) rats. (b) Effect of azothioprine (AZ), chloroquine (CQ) and methotrexate (MTX) on body 
weights of AIA rats. Results are the mean ± standard error for six animals per group. AC, arthritic control; DC, drug control; NT, no treatment; Sal + 
Art, saline and arthritis.Available online http://arthritis-research.com/content/9/5/R91
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simply to control symptoms resulted in various agents being
introduced, which were initially called 'slow-acting
antirheumatic drugs' and were later referred to as DMARDs.
These DMARDs are reported to be widely used in treating
rheumatoid arthritis in humans [29-34]. The goal of DMARDs
is the remission or control of inflammatory joint disease, such
as rheumatoid arthritis. While other arthritis medicines attack
symptoms such as inflammation, DMARDs actually treat the
disease.
It has been reported that DMARDs such as AZ, CQ, MTX and
GS play an important role in slowing the progression of dis-
ease in patients with various autoimmune disorders. It has also
been suggested that low-dose AZ, CQ, GS and MTX in treat-
ment for adjuvant-induced arthritis seems to exert anti-inflam-
matory effects by acting at different levels of the
pathophysiological cascade. AZ, CQ, GS and MTX have been
shown to inhibit T-cell responses during inflammatory
reactions [35-37]. Both GS and MTX were found to inhibit
function of phagocytic cells and both monocytic/lymphocytic
proinflammatory cytokines involved in rheumatoid synovitis,
and this seems to be the key role in the sustained anti-inflam-
matory actions exerted by low-dose MTX [38-48].
Figure 4
Time course of walking speed changes after the induction of arthritis  compared with normal rats Time course of walking speed changes after the induction of arthritis 
compared with normal rats. Treated arthritic rats or untreated arthritic 
rats showed a gradual decrease in velocity from day 2 onwards. 
Arthritic rats treated with azothioprine (AZ), chloroquine (CQ), sodium 
aurothiomalate (gold salt (GS)), methotrexate (MTX) and indometha-
cine, however, exhibited a reversal of the deficit in velocity seen in the 
untreated rats or saline-treated arthritic rats from day 12 onwards. 
Results are the mean ± standard error (n = 6). AC, arthritic control; 
AIA, adjuvant-induced arthritis; DC, drug control; NT, no treatment; Sal 
+ Art, saline and arthritis.
Table 1
Effects of azothioprine, chloroquine, D-penicillamine, sodium aurothiomalate (gold salt) and methotrexate administration over 22 
days on gait parameters of arthritic rats
Day Stride length (cm) Stance time (s) Swing time (s)
Normal control rats 0 14.44 ± 0.40 5.512 ± 0.05 5.842 ± 0.09
22 14.5 ± 0.34 5.53 ± 0.13 6.011 ± 0.87
Arthritic rats
Vehicle (saline) 0 15.33 ± 1.05 5.06 ± 0.01 7.12 ± 1.01
22 6.52 ± 0.57 16.82 ± 0.08 15.32 ± 0.43
Azothioprine (5 mg/kg/day) 0 13.66 ± 0.29 5.97 ± 0.110 7.24 ± 0.079
22 13.16 ± 0.50 7.01 ± 0.091 6.57 ± 0.11
Chloroquine (12.5 mg/kg/day) 0 14.28 ± 0.49 6.11 ± 0.33 6.82 ± 0.523
22 14.01 ± 0.48 6.98 ± 0.055 7.51 ± 0.073
D-Penicillamine (12.5 mg/kg/day) 0 14.95 ± 0.29 4.21 ± 0.017 6.54 ± 0.15
22 8.59 ± 0.31 11.5 ± 0.091 10.01 ± 0.11
Gold Salt (GS, 2.5 mg/kg/day) 0 15.89 ± 0.49 5.78 ± 0.33 6.72 ± 0.48
22 14.98 ± 0.44 6.07 ± 0.055 5.98 ± 0.093
Methotrexate (0.5 mg/kg/week) 0 16.01 ± 0.29 5.59 ± 0.017 5.83 ± 0.075
22 12.79 ± 0.50 7.23 ± 0.09 7.21 ± 0.121
Indomethacine(5 mg/kg/day) 0 14.22 ± 0.49 4.85 ± 0.33 6.07 ± 0.077
22 14.01 ± 0.48 7.17 ± 0.055 8.22 ± 0.23
Results expressed as the mean ± standard error (n = 6) on day 0 and day 22 of the experiment.Arthritis Research & Therapy    Vol 9 No 5    Simjee et al.
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In the present study we describe a possible novel approach to
quantify the hyperalgesia in a rat model of rheumatoid arthritis
using gait analysis. It has previously been reported that gait
changes in the arthritic rat can be used as an objective meas-
ure of chronic pain [23,49]. The principal aim of this study was
to examine the effect of prolonged administration of low doses
of AZ, CQ, D-PEN, GS and MTX on the progression of hind
paw inflammation, disease progression and gait analysis. We
found a strong correlation between parameters obtained from
gait analysis and the disease progression in the adjuvant-
induced arthritic rats. The administration of AZ, CQ, GS and
MTX doses used in this study that had no effect on gait in nor-
mal rats produced a complete reversal of the gait deficits seen
in the untreated, saline-treated and D-PEN-treated arthritic
rats. This suggests that a prolonged administration of low
doses of these DMARDs is effective in preventing the devel-
opment of chronic pain, which, once established, is difficult to
treat with conventional analgesics. These DMARDs also had a
significant effect on disease progression, measured by no fur-
ther weight loss as observed in the untreated or saline-treated
adjuvant-induced arthritis. The DMARDs also significantly
reduced the joint inflammation when administered for a pro-
longed time (over 22 days in case of our study) at low doses.
Conclusion
We demonstrate here that continuous administration of
DMARDs at low doses not only reduces the inflammation as
seen from the macroscopic studies of the arthritic paws, but
also modulates the mechanical hyperalgesia in treated arthritic
rats. In addition, the method of gait analysis showed good evi-
dence of reproducibility in the present study, and our data sug-
gest that the changes in gait may be considered a potential
marker of chronic pain in arthritic rats.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
All four authors participated in the study. SAS conceived of
the study and participated in coordination. SUS designed the
study, drafted the manuscript and performed the analysis of
data. HJ participated in the study and performed the gait anal-
ysis. JQ is a graduate student who provided us the drugs/com-
pounds used in the study. All authors read and approved the
final manuscript.
References
1. Becker N, Sjøgren P, Bech P, Olsen AK, Eriksen J: Treatment out-
come of chronic non-malignant pain patients managed in a
Danish multidisciplinary pain centre compared to general
practice: a randomised controlled trial.  Pain 2000, 84:203-211.
2. Skevington SM: Investigating the relationship between pain
and discomfort and quality of life, using the WHOQOL.  Pain
1998, 76:395-406.
3. Atkinson JH, Slater MA, Patterson TL, Grant I, Garfin SR: Preva-
lence, onset and risk of psychiatric disorders in men with
chronic low back pain: a controlled study.  Pain 1991,
45:111-121.
4. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D: Survery
of chronic pain in Europe: prevalence, impact on daily life, and
treatment.  Eur J Pain 2006, 10:287-333.
5. Severn PS, Fraser SG: Bilateral cataracts and glaucoma
induced by long-term use of oral prednisolone bough over the
internet.  Lancet 2006, 368:618.
6. Biskupiak JE, Brixner DI, Howard KB, Oderda GM: Gastrointesti-
nal complications of over-the-counter nonsteroidal antiinflam-
matory drugs.  J Pain Palliat Care Pharmacother 2006, 20:7-14.
7. Hinz B, Brune K: Pain and osteoarthritis: new drugs and
mechanisms.  Curr Opin Rheumatol 2004, 16:628-633.
8. Schuna AA, Megeff C: New drugs for the treatment of rheuma-
toid arthritis.  Am J Health Syst Pharm 2000, 57:225-234.
9. Meyer-Kirchrath J, Schrör K: Cyclooxygenase-2 inhibition and
side-effects of non-steroidal anti-inflammatory drugs in the
gastrointestinal tract.  Curr Med Chem 2000, 7:1121-1129.
10. Lester RS, Knowles SR, Shear NH: The risks of systemic corti-
costeroid use.  Dermatol Clin 1998, 16:277-287.
11. Lanza FL: Endoscopic studies of gastric and duodenal injury
after the use of ibuprofen, aspirin, and other nonsteroidal anti-
inflammatory agents.  Am J Med 1984, 77:19-24.
12. Silva MA, Ishii-Iwamoto EL, Bracht A, Caparroz-Assef SM, Kimura
E, Cuman RK, Bersani-Amado CA: Efficiency of combined meth-
otrexate/chloroquine therapy in adjuvant-induced arthritis.
Fundam Clin Pharmacol 2005, 19:479-489.
13. Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Khusner I, Wolfe
F: Evidence from clinical trials and long-term observational
studies that disease-modifying anti-rheumatic drugs slow
radiographic progression in rheumatoid arthritis: updating a
1983 review.  Rheumatology (Oxford) 2002, 41:1346-1356.
14. Cai X, Wong YF, Zhou H, Xie Y, Liu ZQ, Jiang ZH, Bian ZX, Xu HX,
Liu L: The comparative study of Sprague–Dawley and Lewis
rats in adjuvant-induced arthritis.  Naunyn-Schmiedeberg's
Arch Pharmacol 2006, 373:140-147.
15. Cai X, Wong YF, Zhou H, Liu ZQ, Xie Y, Jiang ZH, Bian ZX, Xu HX,
Liu L: Manipulation of the induction of adjuvant arthritis in
Sprague–Dawley rats.  Inflamm Res 2006, 55:368-377.
16. Santora K, Rasa C, Visco D, Steinetz B, Bagnell C: Effects of
relaxin in a model of rat adjuvant-induced arthritis.  Ann NY
Acad Sci 2005, 1041:481-485.
17. Gugasyan R, Clouston D, Mandel T, Wicks I: Prevention of
splenic granuloma formation in adjuvant arthritis by 2-acetyl-
4-tetrahydroxybutylimidazole (THI).  Immunol Lett 1997,
58:133-138.
18. Vingsbo C, Jonsson R, Holmdahl R: Avridine-induced arthritis in
rats; a T cell-dependent chronic disease influenced both by
MHC genes and by non-MHC genes.  Clin Exp Immunol 1995,
99:359-363.
19. Rosenthale ME, Capetola RJ: Adjuvant arthritis: immunopatho-
logical and hyperalgesic features.  Fed Proc 1982,
41:2577-2582.
20. Wollheim FA: Current pharmacological treatment of
osteoarthritis.  Drugs 1996, 52(Suppl 3):27-38.
21. Firestein GS: Etiology and pathogenesis of rheumatoid arthri-
tis.  In Kelley's Textbook of Rheumatology Volume 2. Edited by:
Ruddy S, Harris JED, Sledge CB, Budd RC, Sergent JS. Philadel-
phia, PA: W.B. Saunders Company; 1994:921-966. 
22. Kidd BL, Mapp PI, Blake DR, Gibson SJ, Polak JM: Neurogenic
influences in arthritis.  Annals Rheum Dis 1990, 49:649-652.
23. Simjee SU, Pleuvry BJ, Coulthard P: Modulation of the gait defi-
cit in arthritic rats by infusions of muscimol and bicuculline.
Pain 2004, 109:453-460.
24. Coulthard P, Simjee SU, Pleuvry BJ: Gait analysis as a correlate
of pain induced by carrageenan intraplantar injection.  J Neuro-
sci Methods 2003, 128:95-102.
25. Zimmerman M: Ethical guidelines for investigations of experi-
mental pain in conscious animals.  Pain 1983, 16:109-110.
26. Bakharevski O, Stein-Oakley AN, Thomson NM, Ryan PF: Colla-
gen-induced arthritis in rats: contrasting effect of subcutane-
ous versus intradermal inoculation of type II collagen.  J
Rheumatol 1998, 25:1945-1952.
27. Marshall MJ, Worsfold M: Analytical micro-preparative electro-
phoresis: quantitation of phosphoglucose isomerase
isoenzymes.  Anal Biochem 1978, 91:283-292.
28. Capetola RJ, Shriver DA, Rosenthale ME: Suprofen, a new
peripheral analgesic.  J Pharmacol Exp Ther 1980, 214:16-23.Available online http://arthritis-research.com/content/9/5/R91
Page 7 of 7
(page number not for citation purposes)
29. Svensson B, Ahlmén M, Forslind K: Treatment of early RA in clin-
ical practice: a comparative study of two different DMARD/cor-
ticosteroid options.  Clin Exp Rheumatol 2003, 21:327-332.
30. Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell
P, Wells G: Leflunomide for treating rheumatoid arthritis.
Cochrane Database Syst Rev 2003, 1:CD002047.
31. Alarcón GS: Methotrexate use in rheumatoid arthritis: a clini-
cian's perspective.  Immunopharmacology 2000, 47:259-271.
32. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT,
Gömör B, Van Den Bosch F, Nordström D, Bjorneboe O, Dahl R,
et al.: A comparison of the efficacy and safety of leflunomide
and methotrexate for the treatment of rheumatoid arthritis.
Rheumatology (Oxford) 2000, 39:655-665.
33. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff
PJ, Garwood V, Maloley P, Klassen LW, Wees S, et al.: Treatment
of rheumatoid arthritis with methotrexate alone, sulfasalazine
and hydroxychloroquine, or a combination of all three
medications.  N Engl J Med 1996, 334:1287-1291.
34. Porter D, Madhok R, Hunter JA, Capell HA: Prospective trial com-
paring the use of sulfasalazine and auranofin as second line
drugs in patients with rheumatoid arthritis.  Ann Rheum Dis
1992, 51:461-464.
35. Rovensky J, Svík K, Stancíková M, Istok R: Effect of immunostim-
ulatory ribomunyl on the preventive treatment of rat adjuvant
arthritis with cyclosporine and methotrexate.  J Rheumatol
2003, 30:2027-2032.
36. Connolly KM, Stecher VJ, Danis E, Pruden DJ, LaBrie T: Alteration
of interleukin-1 activity and the acute phase response in adju-
vant arthritic rats treated with disease modifying antirheu-
matic drugs.  Agents Actions 1988, 25:94-105.
37. Vinegar R, Truax JF, Selph JL, Lea A, Johnston PR: Azathioprine
treatment of adjuvant arthritis.  J Immunopharmacol 1979,
1:497-520.
38. Rovenský J, Svík K, Matha V, Istok R, Kamarád V, Ebringer L, Fer-
encík M, Stancíková M: Combination treatment of rat adjuvant-
induced arthritis with methotrexate, probiotic bacteria Entero-
coccus faecium, and selenium.  Ann NY Acad Sci 2005,
1051:570-581.
39. Bendele AM, McComb J, Gould T, Frazier J, Chlipala E, Seely J,
Kieft G, Edwards CK 3rd: Effects of PEGylated soluble tumor
necrosis factor receptor type I (PEG sTNF-RI) alone and in
combination with methotrexate in adjuvant arthritic rats.  Clin
Exp Rheumatol 1999, 17:553-560.
40. Segawa Y, Yamaura M, Aota S, Omata T, Tuzuike N, Itokazu Y, Oka
H, Tamaki H, Nakamura T: Methotrexate maintains bone mass
by preventing both a decrease in bone formation and an
increase in bone resorption in adjuvant-induced arthritic rats.
Bone 1997, 20:457-464.
41. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard
JP: Immunosuppressive properties of methotrexate: apopto-
sis clonal deletion of activated peripheral T cells.  J Clin Invest
1998, 15:322-328.
42. Cronstein BN: The mechanism of action of methotrexate.
Rheum Dis Clin North Am 1997, 23:739-755.
43. Wascher TC, Hermann J, Brezinschek R: Serum levels of inter-
leukin-6 and tumor-necrosis-factor-alpha are not correlated to
disease activity in patients with rheumatoid arthritis after
treatment with low-dose methotrexate.  Eur J Clin Invest 1994,
72:535-540.
44. Hu SHK, Mitcho YL, Oronsky AL, Kewar SS: Studies on the
effect of methotrexate on macrophage function.  J Rheumatol
1988, 15:206-209.
45. Cronstein BN, Eberle MA, Gruber HE, Levin RI: Methotrexate
inhibits neutrophil function by stimulating adenosine release
from connective tissue cells.  Proc Natl Acad Sci USA 1991,
88:2441-2445.
46. Johnson WJ, Di Martino MJ, Meunier PC, Murihead KA, Hanna N:
Methotrexate inhibits macrophage activation as well as vascu-
lar and cellular inflammatory events in rat adjuvant induced
arthritis.  J Rheumatol 1988, 15:745-749.
47. Davis P, Johnston C: Effects of gold compounds on function of
phagocytic cells. Comparative inhibition of activated polymor-
phonuclear leukocytes and monocytes from rheumatoid
arthritis and control subjects.  Inflammation 1986, 10:311-320.
48. Scheinberg MA, Santos LM, Finkelstein AE: The effect of
auranofin and sodium aurothiomalate on peripheral blood
monocytes.  J Rheumatol 1982, 9:366-369.
49. Coulthard P, Pleuvry BJ, Brewster M, Wilson KL, Macfarlane TV:
Gait analysis as an objective measure in a chronic pain model.
J Neurosci Methods 2002, 116:197-213.